Kazia Reports 100% Clinical Benefit in Phase 1b TNBC Data and Files Prospectus for 95,110 ADS Offering
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (4.3× avg).
Summary
Kazia reported 100% clinical benefit in six evaluable Stage IV TNBC patients treated with paxalisib, including one durable complete response, and filed a prospectus supplement for a proposed 95,110 ADS offering.
Key Events · Product Development and Regulatory · KZIA
-
100% Clinical Benefit in Stage IV TNBC
All six evaluable patients showed clinical benefit: 1 complete response, 4 partial responses, 1 stable disease (83% objective response rate).
-
Durable Complete Metabolic Response
A 44-year-old patient has had no evidence of disease since November 2025, with sustained elimination of CTC clusters and reduction in exhausted CD8+ T cells.
-
Favorable Safety Profile
No paxalisib-related serious adverse events and no grade 3+ hyperglycemia, stomatitis, or mucositis across the six patients.
-
Proposed 95,110 ADS Offering
The prospectus supplement registers 95,110 ADSs representing 47,555,000 ordinary shares, with Leerink Partners and Guggenheim Securities as placement agents.
Analysis · KZIA · Life Sciences
Kazia's paxalisib achieved a 100% clinical benefit rate in six evaluable Stage IV triple-negative breast cancer patients — five objective responses including one complete response — with no treatment-related serious adverse events. The data is early and from a small open-label trial, but the consistency across all six patients and the durable complete metabolic response since November 2025 are meaningful for a disease with a 12% five-year survival rate. The same filing also registers a proposed offering of 95,110 ADSs, which would dilute existing holders but provides capital to fund the expanded development program.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $13.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.8M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.